Bioinformatics Partnering Agreements Discussed in New Topical Report Published at MarketPublishers.com

17 Nov 2011 • by Natalie Aster
Bioinformatics Partnering Agreements Discussed in New Topical Report Published at MarketPublishers.com

LONDON – The better part of deals entered into by the top healthcare companies are discovery or development stage whereby the licensee accrues a right or an option right to license the licensors bioinformatics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what can be achieved during the negotiation of terms. While many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.

New research report “Bioinformatics Partnering Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Bioinformatics Partnering Agreements
Published: November, 2011
Pages: 960
Price: US$ 2,695

The report is aimed at providing comprehensive understanding and unprecedented access to a wide range of deals and contract documents for over 1,500 bioinformatics deals entered into by the top healthcare companies from pole to pole, as well as explaining how and why these companies enter these deals.

Report Scope:

  • trends in bioinformatics dealmaking in the biopharma industry since 2007;
  • analysis of bioinformatics deal structure;
  • access to headline, upfront, milestone and royalty data;
  • case studies of real-life bioinformatics deals;
  • access to over 1,500 bioinformatics deal documents;
  • the leading bioinformatics deals by value since 2007;
  • most active bioinformatics dealmakers since 2007;
  • the leading bioinformatics partnering resources.

Report Contents:

EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN BIOINFORMATICS DEALMAKING
2.1. Introduction
2.2. Bioinformatics partnering over the years
2.3. Bigpharma bioinformatics dealmaking activity
2.4. Bigpharma not active in bioinformatics partnering
2.5. Bioinformatics partnering by deal type
2.6. Bioinformatics partnering by stage of development
2.7. Bioinformatics partnering by disease type
2.8. Average deal terms for bioinformatics partnering
  2.8.1 Bioinformatics partnering headline values
  2.7.2 Bioinformatics deal upfront payments
  2.7.3 Bioinformatic deal milestone payments
  2.7.4 Bioinformatic royalty rates

CHAPTER 3 – LEADING BIOINFORMATICS DEALS
3.1. Introduction
3.2. Top bioinformatic deals by value
3.3. Top bioinformatics deals involving bigpharma

CHAPTER 4 – BIGPHARMA BIOINFORMATICS DEALS
4.1. Introduction
4.2. How to use bigpharma bioinformatics partnering deals
4.3. Bigpharma bioinformatics partnering company profiles
  Abbott
  Actavis
  Alcon Labs
  Allergan
  Amgen
  Apotex
  Astellas
  AstraZeneca
  Baxter International
  Bayer
  Biogen Idec
  Boehringer Ingelheim
  Bristol-Myers Squibb
  Celgene
  Cephalon
  Chugai
  CSL
  Daiichi Sankyo
  Dainnipon Sumitomo
  Eisai
  Eli Lilly
  Forest Laboratories
  Genzyme
  Gilead Sciences
  GlaxoSmithKline
  Hospira
  Johnson & Johnson
  Kyowa Hakko Kirin
  Lundbeck
  Menarini
  Merck & Co
  Merck KGaA
  Mitsubishi-Tanabe
  Mylan
  Novartis
  Novo Nordisk
  Nycomed
  Otsuka
  Pfizer
  Roche
  Sanofi
  Servier
  Shionogi
  Shire
  Stada
  Takeda
  Teva
  UCB
  Warner Chilcott
  Watson

CHAPTER 5 – BIOINFORMATICS DEALMAKING DIRECTORY
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
  Discovery
  Preclinical
  Phase I
  Phase II
  Phase III
  Regulatory
  Formulation
  Marketed
5.4. By deal type
  Asset purchase
  Bigpharma outlicensing
  Co-development
  Collaborative R&D
  Co-market
  Contract service
  Co-promotion
  CRADA
  Cross-licensing
  Development
  Distribution
  Equity purchase
  Evaluation
  Grant
  Joint venture
  Licensing
  Litigation
  Loan
  Manufacturing
  Manufacturing - OEM
  Marketing
  Option
  Promotion
  Research
  Settlement
  Spin out
  Sub-license
  Supply
  Cardiovascular
  Central Nervous System
  Cosmetics
  Dental
  Dermatology
  Gastrointestinal
  Genetic disorders
  Genitourinary
  Hematology
  Hormonal
  Hospital care
  Immunology
  Infectives
  Inflammatory
  Metabolic
  Musculoskeletal
  Oncology
  Ophthalmics
  Respiratory
  Sensory organs

CHAPTER 6 – PARTNERING RESOURCE CENTER
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

APPENDICES
Appendix 1 – Deal type definitions
Appendix 2 – Example bioinformatics partnering agreement
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES
Figure 1: Bioinformatics partnering since 2007
Figure 2: Bigpharma – top 50 – bioinformatics deals 2007 to 2011
Figure 3: Inactive bigpharma in bioinformatics partnering 2007-2011
Figure 4: Bioinformatics partnering by deal type since 2007
Figure 5: Bioinformatics partnering by deal type since 2007
Figure 6: Bioinformatics partnering by disease type since 2007
Figure 7: Bioinformatics partnering by oncology target since 2007
Figure 8: Bioinformatics deals with a headline value – by stage of development
Figure 9: Bioinformatics deal headline value distribution – discovery stage, US$million
Figure 10: Bioinformatic deal headline value distribution – discovery stage, US$million - detail
Figure 11: Bioinformatic deals with upfront payment values – by stage of development
Figure 12: Bioinformatic deal upfront payment distribution – discovery stage, US$million
Figure 13: Bioinformatic deal upfront payment distribution – discovery stage, US$million - detail
Figure 14: Bioinformatic deals with milestone payments
Figure 15: Bioinformatic deal milestone payment distribution, US$million
Figure 16: Bioinformatic deals with royalty rates
Figure 17: Top bioinformatics deals by value since 2007
Figure 18: Top bioinformatics deals signed by bigpharma value since 2007
Figure 19: Online partnering resources
Figure 20: Forthcoming partnering events
Figure 21: Deal type definitions
Figure 22: Bioinformatics partnering agreement between Amgen and IBM, October 2008

More new research reports by the publisher can be found at CurrentPartnering page.

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

MarketPublishers.com